Pharmaceutical company expenses: Cost of sales, Marketing, R&D compared

April 19, 2000

1999 Data

All data points are percentages of sales unless specified otherwise

      

 Company
 Cost of Goods
 Marketing & Administrative
 R&D
 Abbott   45.4%   21.7%    9.1% 
 American Home Products   27.3%   37.2%   12.8% 
 AMGEN   13.2%*   19.6%   24.6% 
 Biogen   17.9%*   18.4%   27.8% 
 Bristol-Myers Squibb   27.4%   34.6%    9.1% 
 Dupont   63.1%    9.6%    6.0% 
 Eli Lilly   21.0%   27.6%   17.8% 
 Genentech   18.0%*   33.0%   26.0% 
 Glaxo Wellcome   20.0%   35.2%   14.6% 
 Johnson & Johnson   30.7%   38.2%   9.5% 
 Merck   53.6%   15.9%    6.3% 
 Novartis   N.A   N.A   12.4% 
 Novartis (Pharmaceutical segment)   N.A   N.A   18.3% 
 Pharmacia   26.1%   38.6%   19.8% 
 Pfizer  15.6%   39.2%   17.1% 
 Roche   N.A   N.A   13.7% 
 Schering-Plough  19.6%   37.4%   13.0% 
 SmithKline Beecham   29.2%   38.2%   12.1% 
 Warner-Lambert   23.5%   46.1%    9.7% 

*Percentage of Product Sales

Source: Company SEC 10K Filings and Company Annual Reports

Corrections or suggestions to Thiru Balasubramaniam thiru@cptech.org.
 
 

| CPT home page | CPT Health Care and Intellectual Property page | CPT Health Care and Economics page |